Nettet29. sep. 2024 · The MOUNTAINEER trial demonstrated promising activity for tucatinib and trastuzumab, with more than half of evaluable patients with RAS wild-type and HER2 … Nettet11. feb. 2024 · MOUNTAINEER is a phase II trial for people diagnosed with metastatic HER2-positive colorectal cancer or HER2-positive disease that can’t be completely removed with surgery. This trial studies how the drug tucatinib works and how safe it is when given with trastuzumab and when given by itself. The use of tucatinib described …
Tucatinib Plus Trastuzumab in Patients With HER2
Nettet1. okt. 2024 · MOUNTAINEER is a multicenter open-label single-arm phase II trial. Pts with RAS WT mCRC had HER2 amplification/overexpression by NGS, FISH, or IHC (3+ or 2+ and amplified by FISH). Prior treatment with 5FU, oxaliplatin, irinotecan, and an anti-VEGF antibody was required. Prior anti-HER2 therapy was excluded. Nettet28. jul. 2024 · Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC Jul 28, 2024 Tanios Bekaii-Saab, MD Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER... huntsman port neches jobs
MOUNTAINEER:open-label, phase II study of tucatinib combined …
NettetThe primary analysis of MOUNTAINEER (NCT03043313) in cohorts A+B treated with tucatinib (TUC) + trastuzumab (Tras) was previously reported and showed tolerability and a confirmed objective response rate (cORR) per blinded independent central review (BICR) of 38.1%. Here, additional results of TUC monotherapy (cohort C) are reported. Methods Nettet1. apr. 2024 · The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer (mCRC), … Nettet1 INSPIRED BY PATIENTS. DRIVEN BY SCIENCE. J.P. Morgan Healthcare Conference. Clay Siegall, Ph.D. President and Chief Executive Officer. January 10, 2024 mary beth jalickee